Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. By: Wellington Management Company LLP, as Investment Adviser By: /s/ Jennifer C. Boylan, Authorized Signatory
Stock symbol
ZBIO
Transactions as of
Sep 16, 2024
Transactions value $
$0
Form type
4
Date filed
9/18/2024, 05:16 PM
Previous filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZBIO Common Stock Conversion of derivative security +181K 181K Sep 16, 2024 Direct F1
transaction ZBIO Common Stock Conversion of derivative security +420K +232.66% 601K Sep 16, 2024 Direct F1, F2
transaction ZBIO Common Stock Conversion of derivative security +201K +33.4% 802K Sep 16, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZBIO Series A Convertible Preferred Stock Conversion of derivative security -1.57M -100% 0 Sep 16, 2024 Common Stock 181K Direct F1
transaction ZBIO Series B Convertible Preferred Stock Conversion of derivative security -3.65M -100% 0 Sep 16, 2024 Common Stock 420K Direct F2
transaction ZBIO Series C Convertible Preferred Stock Conversion of derivative security -1.74M -100% 0 Sep 16, 2024 Common Stock 201K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F2 On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F3 On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.